Latest Form 4 insider transactions

NYSE
Banco Santander announces exchange offers to acquire the outstanding minority interest in Santander Brasil, providing shareholders with a premium and increased liquidity.
NASDAQ
Stephen Mitchell Howell Jr., COO of Riot Platforms, Inc., reported a transaction in 21,198 shares of common stock on August 12, 2026.
NYSE
William Landman, a Director of Zeta Global Holdings Corp., reported a transaction in 22,153 shares of common stock on August 12, 2026.
NYSE
David H Li, President & CEO and a Director of Ingevity Corp, sold 10,000 shares of common stock on August 12, 2026.
NASDAQ
John P Skenesky, VP and Division Manager of Mcgrath Rentcorp, reported a transaction in 6,077 shares of common stock on August 12, 2026.
NASDAQ
Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc, sold 31,641 shares of common stock on August 12, 2026 for $292.06 per share.
NYSE
Jesus Llorca, EVP & CFO of SEACOR Marine Holdings Inc., sold 10,270 shares of common stock on August 12, 2026.
NYSE
Constantine Petropoulos, See Remarks of Park Aerospace Corp, received 25,000 shares of common stock on August 12, 2026.
NYSE
Banco Santander announces details of its proposed exchange offers to acquire the outstanding minority interest in Santander Brasil, outlining the exchange ratio, adjustments, and strategic rationale.
NYSE
Rachel Maureen Moore, EVP, Corporate Services of Ovintiv Inc., sold 7,753 shares of common stock on August 12, 2026 for $63.32 per share.
NYSE
Jeremy Fox-Geen, Chief Financial Officer of Circle Internet Group, Inc., sold 8,476 shares of common stock on August 13, 2026 for $75.00 per share.
NASDAQ
Tsafi Goldman, Chief Legal & Governance Ofcr. of Payoneer Global Inc., reported a transaction in 10,369 shares of common stock on August 13, 2026.
NYSE
Benjamin D Chereskin, a Director of Cinemark Holdings, Inc., received 5,439 shares of common stock on June 15, 2026.
NASDAQ
Liliana Esposito, Chf Corp Affrs & Sustnblty Ofc of Wendy's Co, reported multiple transactions in common stock on August 12, 2026.
NYSE
Aglika Dotcheva, Chief Financial Officer of Riskified Ltd., sold 260,000 shares of common stock on August 12, 2026.
NASDAQ
Aaron M. Kale, Chief Accounting Officer of Wendy's Co, reported multiple transactions in common stock on August 12, 2026.
NYSE
Darcy Antonellis, a Director of Cinemark Holdings, Inc., received 5,439 shares of common stock on June 15, 2026.
NASDAQ
Lindsay J. Radkoski, CMO, U.S. of Wendy's Co, reported multiple transactions in common stock on August 12, 2026.
NAS
Alternative Credit Income Fund has filed a Rule 425 document detailing the launch of a new investment fund, outlining its structure and objectives.
NYSE
Assaf Feldman, Chief Strategy Officer - Tech, a Director and 10% owner of Riskified Ltd., sold 656,096 shares of common stock on August 12, 2026.
NASDAQ
Matthew P Spessard, Chief Information Officer of Wendy's Co, reported multiple transactions in common stock on August 12, 2026.
NYSE
Mark A Esquivel, President & COO of Park Aerospace Corp, sold 40,000 shares of common stock on August 13, 2026 for $37.00 per share.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., sold 16,142 shares of common stock on August 13, 2026 for $27.61 per share.
NASDAQ
Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc., reported multiple transactions in common stock on August 12, 2026.
NASDAQ
Jennifer Larson, Chief Financial Officer of Bicara Therapeutics Inc., received 285,000 shares of common stock on August 12, 2026.
NASDAQ
LivePerson provides detailed instructions for employee shareholders to vote on the proposed merger with SoundHound AI, emphasizing the importance of every vote.
NYSE
Bryan Lee Stovall, COO - Metal Coatings of Azz Inc, sold 2,677 shares of common stock on August 14, 2026 for $150.07 per share.
NASDAQ
Joanne M. Donovan, CMO of Edgewise Therapeutics, Inc., sold 9,441 shares of common stock on August 12, 2026.
NASDAQ
Alan J Russell, Chief Scientific Officer and a Director of Edgewise Therapeutics, Inc., sold 5,901 shares of common stock on August 12, 2026.
NASDAQ
John R Moore, General Counsel of Edgewise Therapeutics, Inc., sold 5,016 shares of common stock on August 12, 2026.